Lantheus vs Myriad Genetics
LNTH and MYGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LNTH and MYGN compare
Lantheus is the larger company, worth 12 times as much as Myriad Genetics ($6.6B against $533M).
Lantheus grew revenue faster over the last twelve months (2.3% versus −3.2% for Myriad Genetics).
Lantheus keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with −14.0% at Myriad Genetics.
Lantheus scores higher on the StockData Score (11 against 6 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LNTH | MYGN |
|---|---|---|
| Size and price | ||
| Market cap | $6.6B | $533M |
| Share price | $101.72 | $5.57 |
| Change, 1 year | 91.5% | −12.3% |
| Change, 5 years | 265% | −79.1% |
| Beta (5Y) | 0.41 | −0.10 |
| Employees | 1,193 | 2,700 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 5 (better) | 3 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 24.6× | – |
| P/S | 4.3× | 0.7× (better) |
| P/B | 5.1× | 1.8× (better) |
| EV/EBITDA | 16.9× | – |
| PEG | 0.24 | – |
| Fair value | $91.21 | – |
| Margin of safety | −11.5% | – |
| Growth | ||
| Revenue growth (TTM) | 2.3% (better) | −3.2% |
| Revenue growth, 5Y average | 35.3% (better) | −0.63% |
| Net income growth (TTM) | 1.6% | – |
| EPS growth (TTM) | 9.5% | – |
| Profitability | ||
| Gross margin | 60.1% | 68.8% (better) |
| Operating margin | 19.4% (better) | −12.2% |
| Net margin | 17.7% (better) | −14.0% |
| Return on equity | 22.2% (better) | −32.5% |
| Return on invested capital | 19.7% (better) | −22.8% |
| Financial health | ||
| Debt / equity | 0.44 | 0.40 (better) |
| Net debt / EBITDA | −0.06 | – |
| Interest coverage | 15.3× (better) | −6.0× |
| Current ratio | 3.06 (better) | 2.21 |
| Altman Z-score | 5.52 (better) | −0.62 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 117% | 94.1% |
| Held by insiders | 2.3% | 7.2% |
| Insider net buying, 12 months | – | $655K |
| Short interest, % of float | 5.7% | 9.5% |
Go deeper
- LNTH stock overview
- LNTH income statement
- LNTH valuation and score
- MYGN stock overview
- MYGN income statement
- MYGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.